Document Detail


p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease.
MedLine Citation:
PMID:  21796446     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Medulloblastoma (MB) is the most common malignant primary brain tumour in childhood. Metastatic disease (M+) at diagnosis is the most important negative prognostic clinical marker and, despite craniospinal irradiation and intensive chemotherapy, it remains one of the leading causes of treatment failure. To date, few clinical and biological data have been evaluated to obtain an additional prognostic profile for these high-risk patients. In this study, 169 patients with metastatic MB registered in the multicentre HIT2000 trial of the German Society of Pediatric Oncology and Haematology (GPOH) have been investigated to determine the importance of p53 protein expression in predicting survival. At a median follow-up of 4.1 years, 159 patients with p53-negative tumours had significantly better four-year event-free survival (EFS) and progression-free survival (PFS) (56 ± 11, 59 ± 4%) than 10 patients with p53-positive tumours (40 ± 16, 40 ± 16%; P = 0.018 for EFS, P = 0.007 for PFS, respectively). Furthermore, four-year overall survival (OS) of children with p53-negative tumours was higher than for children with p53-positive tumours (72 ± 4 vs. 35 ± 18%, P = 0.05). Three of the p53-positive MBs harbored a point mutation in the TP53 gene. p53 protein assessment by immunohistochemistry may be a useful tool for sub-stratification of metastatic high-risk MB patients.
Authors:
Marco Gessi; André O von Bueren; Stefan Rutkowski; Torsten Pietsch
Related Documents :
18510166 - Solitary osteochondroma long-term follow-up.
10476526 - Pericardial mesothelioma in a dog: long-term survival after pericardiectomy in combinat...
21569996 - Randomized phase ii study comparing efficacy and safety of combination-therapy trastuzu...
22139966 - Cessation of vascular endothelial growth factor-targeted therapy in patients with metas...
19940546 - Radiation schedules in relation to obliteration and complications in hypofractionated c...
9451046 - Aggressive surgical management in localized pulmonary mycotic and nonmycotic infections...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-7-28
Journal Detail:
Title:  Journal of neuro-oncology     Volume:  -     ISSN:  1573-7373     ISO Abbreviation:  -     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-7-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309335     Medline TA:  J Neurooncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Institute of Neuropathology, University of Bonn Medical Center, Sigmund-Freud-Strasse 25, 53127, Bonn, Germany, mgessimd@yahoo.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The two endo-?-N-acetylglucosaminidase genes from Arabidopsis thaliana encode cytoplasmic enzymes co...
Next Document:  ProSeal™laryngeal mask in normal weight and obese patients : Oxygenation under pressure-controlled v...